Admissions for bronchiolitis at children's hospitals before and during the COVID-19 pandemic

KA Remien, JZ Amarin, CM Horvat… - JAMA Network …, 2023 - jamanetwork.com
Importance The COVID-19 pandemic has been associated with a transient decrease in
bronchiolitis hospitalizations compared with prepandemic patterns, but current effects …

A historical perspective on Respiratory Syncytial Virus prevention: a journey spanning over half a century from the setback of an inactive vaccine candidate to the …

A Noor, LR Krilov - Journal of the Pediatric Infectious Diseases …, 2024 - academic.oup.com
The efforts to prevent respiratory syncytial virus (RSV) infection in infants span over half a
century. RSV vaccine development began in the 1960s, and it confronted a significant …

A review of respiratory syncytial virus epidemiology among children: linking effective prevention to vulnerable populations

D Daniels - Journal of the Pediatric Infectious Diseases Society, 2024 - academic.oup.com
Respiratory syncytial virus (RSV) is the greatest contributor to lower respiratory tract
infections (LRTI) in children less than 5 years of age and the leading cause for infant …

Genotypic and phenotypic characterisation of respiratory syncytial virus after nirsevimab breakthrough infections: a large, multicentre, observational, real-world study

S Fourati, A Reslan, J Bourret… - The Lancet Infectious …, 2024 - thelancet.com
Background Nirsevimab, a long-acting monoclonal antibody, has been approved for the
prevention of respiratory syncytial virus (RSV) infection in infants. In France, more than 210 …

Respiratory syncytial virus (RSV) prevention: perception and willingness of expectant parents in the Netherlands

LM Harteveld, LM van Leeuwen, SM Euser, LJ Smit… - Vaccine, 2025 - Elsevier
Background Respiratory syncytial virus (RSV) is a leading cause of infant respiratory
disease. Recent approval of preventive measures like a long-acting monoclonal antibody …

Acceptance and safety of the RSV-preventive treatment of newborns with nirsevimab in the maternity department: a prospective longitudinal cohort study in France

CO de Sentuary, C Testard, M Lagrée, M Leroy… - …, 2025 - thelancet.com
Background To evaluate the acceptance and safety of the treatment of newborns with
nirsevimab (a long-acting monoclonal antibody designed to prevent respiratory syncytial …

Pediatric Respiratory Syncytial Virus Hospitalizations and Respiratory Support After the COVID-19 Pandemic

ZA Winthrop, JM Perez, SJ Staffa… - JAMA Network …, 2024 - jamanetwork.com
Importance After the COVID-19 pandemic, there was a surge of pediatric respiratory
syncytial virus (RSV) infections, but national data on hospitalization and intensive care unit …

Pediatric Respiratory Syncytial Virus Hospitalizations, 2017-2023

T Fitzpatrick, SA Buchan, S Mahant, L Fu… - JAMA Network …, 2024 - jamanetwork.com
Importance Respiratory syncytial virus (RSV) transmission was disrupted worldwide
following the COVID-19 pandemic, and further study is required to better understand these …

Inpatient service utilization amongst infants diagnosed with Respiratory Syncytial Virus infection (RSV) in the United States

JR Gantenberg, KD Thompson, R van Aalst, DM Smith… - PloS one, 2025 - journals.plos.org
Introduction Respiratory syncytial virus (RSV) is the leading cause of hospitalization among
US infants. Characterizing service utilization during infant RSV hospitalizations may provide …

Safety of RSV Vaccine among Pregnant Individuals: A Real-World Pharmacovigilance Study Using Vaccine Adverse Event Reporting System

A Alami, S Perez-Lloret, DR Mattison - medRxiv, 2024 - medrxiv.org
Objectives To describe the post-marketing safety of RSVPreF among pregnant individuals.
Design This case series study analyzed adverse event (AE) reports submitted to the US …